Literature DB >> 30402860

Long non-coding RNA expression profile in permanent atrial fibrillation patients with rheumatic heart disease.

B Mei1, H Liu, S Yang, M-Y Liang, Y Yue, S-Q Huang, J Hou, G-X Chen, Z-K Wu.   

Abstract

OBJECTIVE: Atrial fibrillation (AF) is the most common type of arrhythmia, especially in rheumatic heart disease (RHD) patients. The differences in structural remodeling and electrical remodeling between the left and right atrium associated with AF in RHD patients are well known, and alterations in the expression profiles of long noncoding RNAs (lncRNAs) in the left atrium have also been investigated. However, the role of lncRNAs in the right atrium (RA) remains largely unknown. PATIENTS AND METHODS: We identified differentially expressed lncRNAs in RA tissues of RHD patients with AF or a normal sinus rhythm (NSR) using microarray analysis. Then, we performed gene ontology (GO) and KEGG pathway analyses for functional annotation of the deregulated lncRNAs. Finally, we constructed a lncRNA-mRNA co-expression network.
RESULTS: Of the 22,829 human non-coding RNAs analyzed, a total of 1,909 long non-coding RNAs were detected. A total of 182 lncRNAs (117 downregulated and 65 upregulated) were shown to be differentially expressed (fold-change > 1.5) in AF patients compared with NSR patients. Many lncRNAs might be partially involved in an AF-related pathway.
CONCLUSIONS: AF dysregulates the expression of lncRNAs in the RA of RHD patients. These findings may be useful for exploring potential therapeutic treatments for AF in RHD patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30402860     DOI: 10.26355/eurrev_201810_16165

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

1.  Identification of atrial-enriched lncRNA Walras linked to cardiomyocyte cytoarchitecture and atrial fibrillation.

Authors:  Carlos García-Padilla; Jorge N Domínguez; Valeria Lodde; Rachel Munk; Kotb Abdelmohsen; Myriam Gorospe; Veronica Jiménez-Sábado; Antonino Ginel; Leif Hove-Madsen; Amelia E Aránega; Diego Franco
Journal:  FASEB J       Date:  2022-01       Impact factor: 5.834

Review 2.  Research Progress of LncRNAs in Atrial Fibrillation.

Authors:  Wenhui Wang; Bei Tian; Zhongping Ning; Xinming Li
Journal:  Mol Biotechnol       Date:  2022-02-02       Impact factor: 2.695

3.  Altered Expression of Transfer-RNA-Derived Small RNAs in Human With Rheumatic Heart Disease.

Authors:  Zhao-Yu Yang; Peng-Fei Li; Zhi-Qing Li; Tao Tang; Wei Liu; Yang Wang
Journal:  Front Cardiovasc Med       Date:  2021-12-01

Review 4.  Exosomes and Exosomal Non-coding RNAs Are Novel Promises for the Mechanism-Based Diagnosis and Treatments of Atrial Fibrillation.

Authors:  Chaofeng Chen; Qingxing Chen; Kuan Cheng; Tian Zou; Yang Pang; Yunlong Ling; Ye Xu; Wenqing Zhu
Journal:  Front Cardiovasc Med       Date:  2021-12-01

Review 5.  A narrative review of non-coding RNAs in atrial fibrillation: potential therapeutic targets and molecular mechanisms.

Authors:  Lan Zhang; Xi Wang; Congxin Huang
Journal:  Ann Transl Med       Date:  2021-09

6.  Construction and Analysis of the lncRNA-miRNA-mRNA Network Based on Competing Endogenous RNA in Atrial Fibrillation.

Authors:  Xiangyu Ke; Junguo Zhang; Xin Huang; Shuai Li; Meifang Leng; Zebing Ye; Guowei Li
Journal:  Front Cardiovasc Med       Date:  2022-01-24

Review 7.  Role of Non-Coding Variants in Brugada Syndrome.

Authors:  Adrian Pérez-Agustín; Mel Lina Pinsach-Abuin; Sara Pagans
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

Review 8.  Long Non-Coding RNAs in Atrial Fibrillation: Pluripotent Stem Cell-Derived Cardiomyocytes as a Model System.

Authors:  Emre Bektik; Douglas B Cowan; Da-Zhi Wang
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

Review 9.  Genetics and Epigenetics of Atrial Fibrillation.

Authors:  Estefanía Lozano-Velasco; Diego Franco; Amelia Aranega; Houria Daimi
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.